Assessing Lateralization Index of Adrenal Venous Sampling for Surgical Indication in Primary Aldosteronism.

Primary aldosteronism adrenal venous sampling lateralization index surgical outcome

Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 11 09 2023
revised: 26 04 2024
accepted: 13 05 2024
medline: 15 5 2024
pubmed: 15 5 2024
entrez: 15 5 2024
Statut: aheadofprint

Résumé

Clinical practice guidelines recommend the Lateralization Index (LI) as the standard for determining surgical eligibility in primary aldosteronism (PA). Our goal was to identify the optimal LI cut-offs in adrenal venous sampling (AVS) for diagnosing PA that is amenable to surgical cure. We conducted a retrospective international cohort study across 16 institutions in 11 countries, including 1,550 patients with PA who underwent AVS, with and/or without ACTH stimulation. The establishment of optimal cut-offs was informed by a survey of 82 PA patients in Japan, aimed at determining the LI cut-off aligned with patient expectations for a surgical cure rate. The survey revealed that a median cure rate expectation of 80% would motivate PA patients towards undergoing adrenalectomy. The optimal LI cut-offs achieving an adjusted positive predictive value (PPV) of 80% were identified as 3.8 for unstimulated AVS and 3.4 for ACTH-stimulated AVS. Furthermore, a contralateral ratio of less than 0.4 and the detection of an adrenal nodule on CT imaging were identified as independent predictors of surgically curable PA. Incorporating these factors with the optimal LI cut-offs, the adjusted PPV increased to 96.6% for unstimulated AVS and 89.6% for ACTH-stimulated AVS. No clear differences in predictive ability between unstimulated and ACTH-stimulated LI were found. The present study clarified the optimal LI cut-offs for without and with ACTH stimulation. The presence of contralateral suppression and adrenal nodule on CT imaging seems to provide additional available information besides LI for surgical indication.

Sections du résumé

BACKGROUND BACKGROUND
Clinical practice guidelines recommend the Lateralization Index (LI) as the standard for determining surgical eligibility in primary aldosteronism (PA). Our goal was to identify the optimal LI cut-offs in adrenal venous sampling (AVS) for diagnosing PA that is amenable to surgical cure.
METHODS METHODS
We conducted a retrospective international cohort study across 16 institutions in 11 countries, including 1,550 patients with PA who underwent AVS, with and/or without ACTH stimulation. The establishment of optimal cut-offs was informed by a survey of 82 PA patients in Japan, aimed at determining the LI cut-off aligned with patient expectations for a surgical cure rate.
RESULTS RESULTS
The survey revealed that a median cure rate expectation of 80% would motivate PA patients towards undergoing adrenalectomy. The optimal LI cut-offs achieving an adjusted positive predictive value (PPV) of 80% were identified as 3.8 for unstimulated AVS and 3.4 for ACTH-stimulated AVS. Furthermore, a contralateral ratio of less than 0.4 and the detection of an adrenal nodule on CT imaging were identified as independent predictors of surgically curable PA. Incorporating these factors with the optimal LI cut-offs, the adjusted PPV increased to 96.6% for unstimulated AVS and 89.6% for ACTH-stimulated AVS. No clear differences in predictive ability between unstimulated and ACTH-stimulated LI were found.
CONCLUSIONS AND RELEVANCE CONCLUSIONS
The present study clarified the optimal LI cut-offs for without and with ACTH stimulation. The presence of contralateral suppression and adrenal nodule on CT imaging seems to provide additional available information besides LI for surgical indication.

Identifiants

pubmed: 38747468
pii: 7673657
doi: 10.1210/clinem/dgae336
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Auteurs

Hiroki Kobayashi (H)

Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan.

Yoshihiro Nakamura (Y)

Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan.

Masanori Abe (M)

Division of Nephrology, Hypertension, and Endocrinology, Nihon University School of Medicine, Tokyo, Japan.

Oskar Ragnarsson (O)

Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.
The Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Göteborg, Sweden.
Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, Göteborg, Sweden.

Eleftheria Gkaniatsa (E)

Institution of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden.

Marianne Aa Grytaas (MA)

Department of Medicine, Haukeland University Hospital, Bergen, Norway.

Kristian Løvås (K)

Department of Medicine, Haukeland University Hospital, Bergen, Norway.

Norio Wada (N)

Department of Diabetes and Endocrinology, Sapporo City General Hospital, Sapporo, Japan.

Takamasa Ichijo (T)

Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.

Daniel A Heinrich (DA)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Ziemssenstr. München, Germany.

William Drake (W)

Department of Endocrinology, St Bartholomew's Hospital, London, UK.

Sam O'Toole (S)

Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Department of Endocrinology, Royal Hallamshire Hospital, Sheffield, UK.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

Tomaz Kocjan (T)

Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Darko Kastelan (D)

School of Medicine, University of Zagreb, Zagreb, Croatia.
Division of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia.

Ivana Kraljevic (I)

School of Medicine, University of Zagreb, Zagreb, Croatia.
Division of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia.

Koichi Yamamoto (K)

Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Mika Tsuiki (M)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Simon Kloock (S)

Department of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital Würzburg, Würzburg, Germany.

Ulrich Dischinger (U)

Department of Internal Medicine I, Division of Endocrinology and Diabetology, University Hospital Würzburg, Würzburg, Germany.

Mirko Parasiliti-Caprino (M)

Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.

Gruber Sven (G)

Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.

Ariadni Spyroglou (A)

Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
2nd Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Raluca Maria Furnica (RM)

Department of Endocrinologie and Nutrition, Cliniques Universitaires Saint Luc, Université catholique de Louvain, Bruxelles, Belgium.

Francesco Fallo (F)

Department of Medicine, Clinica Medica 3, University of Padova, Padova, Italy.

Giuseppe Maiolino (G)

Department of Medicine, Clinica Medica 3, University of Padova, Padova, Italy.

Mitsuhiro Kometani (M)

Department of Health Promotion and Medicine of the Future, Kanazawa University Graduate School of Medicine, Kanazawa, Ishikawa 920-8641, Japan.

Vin-Cent Wu (VC)

Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100, Taiwan.

Felix Beuschlein (F)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Ziemssenstr. München, Germany.
Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
The LOOP Zurich Medical Research Center, Zurich, Switzerland.

Martin Reincke (M)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, Ziemssenstr. München, Germany.

Mitsuhide Naruse (M)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Endocrine Center, Ijinkai Takeda General Hospital, Kyoto, Japan.

Classifications MeSH